what are the Recommendations for Selecting an Anticoagulant Regimen—
Balancing Risks and Benefits
Referenced studies that support new or modified recommendations
are summarized in Online Data Supplements 1 and 2.?
For patients with AF and an elevated CHADS-VASc score of 2 or greater 2 2 in men or 3 or greater in women, oral anticoagulants are recommended. Options include: Warfarin (LOE: A)S4.1.1-5?S4.1.1-7 Dabigatran (LOE: B)S4.1.1-8 Rivaroxaban (LOE: B)S4.1.1-9 Apixaban (LOE: B),S4.1.1-10 or Edoxaban (LOE: B-R)S4.1.1-11 MODIFIED: This recommendation has been updated in response to the approval of edoxaban, a new factor Xa inhibitor. More precision in the use of CHADS-VASc scores is 2 2 specified in subsequent recommendations. The LOEs for warfarin, dabigatran, rivaroxaban, and apixaban have not been updated for greater granularity as per the new LOE system. (Section 4.1. in the 2014 AF Guideline) The original text can be found in Section 4.1 of the 2014 AF guideline. Additional information about the comparative effectiveness and bleeding risk of NOACs can be found in Section